Infectious Diseases in Critical Care Medicine

68. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin
    North Am 1990; 4:409–432.


69. Grayson ML. Diabetic foot infections: antimicrobial therapy. Infect Dis Clin North Am 1995; 9:143–161.


70. Centers for Disease Control and Prevention. Vancomycin-resistantStaphylococcus aureus—Pennsylvania.
    MMWR Morb Mortal Wkly Rep 2002; 51:902.


71. Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection
    drug users: a case control study. Clin Infect Dis 2001; 33:35–40.


72. Chen JL, Fullerton KE, Flynn NM. Necrotizing fasciitis associated with injection drug use. Clin Infect
    Dis 2001; 33:6–15.


73. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am
    2002; 16:697–712.


74. Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings,
    and current perspectives on diagnosis and treatment. Clin Infect Dis 2006; 43(11):1436–1446.


75. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20:485–506.


76. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review
    of 929 reported cases. Clin Infect Dis 2005; 41(5):634–653.


77. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations,
    and management. Infect Dis Clin North Am 2006; 20(3):581–607.


78. Greene SL, Su WP, Muller SA. Report of clinical, histopathologic, and bacteriologic aspects of eight
    cases. J Am Acad Dermatol 1984; 11:781–787.


79. Huminer D, Siegman-Igra Y, Morduchowicz G, et al. Ecthyma gangrenosum without bacteremia.
    Report of six cases and review of the literature. Arch Intern Med 1987; 147(2):299–301.


80. Sevinsky LD, Viecens C, Ballesteros DO, et al. Ecthyma gangrenosum: a cutaneous manifestation of
    Pseudomonas aeruginosa sepsis. J Am Acad Dermatol 1993; 29(1):104–106.


81. Horan TC, Gaynes RP, Martone WJ, et al. CDC Definitions of nosocomial surgical site infections,
    1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol
    1992; 13:606–608.


82. Melish ME, Glasgow LA. The staphylococcal scalded-skin syndrome. N Engl J Med 1970; 282:
    1114–1119.


83. Dajani AS. The scalded skin syndrome: relation to phage group II staphylococci. J Infect Dis 1972;
    125:548–551.


84. Kondo IS, Sakuri S, Sarai Y, et al. Two serotypes of exfoliatin and their distribution in Staphylococcal
    strain isolated from patients with scalded skin syndrome. J Clin Microbiol 1975; 5:397–400.


85. Yamasaki O, Yamguchi T, Sugai M, et al. Clinical manifestations of Staphylococcal scalded-skin
    syndrome depend on serotypes of exfoliative toxins. J Clin Microbiol 2005; 43:1890–1893.


86. Ladhani S, Joannou CL, Lochrie DP, et al. Clinical, microbial, and biochemical aspects of the exfoliative
    toxins causing Staphylococcal scalded-skin syndrome. Clin Microbiol Rev 1999; 12:224–242.


87. Lina G, Gillet Y, Vandenesch F, et al. Toxin involvement in staphylococcal scalded skin syndrome.
    Clin Infect Dis 1997; 25:1369–1373.


88. Elias PM, Fritsch P, Epstein EH Jr. Staphylococcal scalded skin syndrome. Arch Dermatol 1997;
    113:207–219.


89. Ladhani S, Evans RW. Staphylococcal scalded skin syndrome. Arch Dis Child 1998; 78:85–88.


90. Gemmell CG. Staphylococcal scalded skin syndrome. J Med Microbiol 1995; 43:318–327.


91. Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults: a clinical review
    illustrated with a case. J Am Acad Dermatol 1984; 30:319–324.


92. Brochers SL, Gomez EC, Isseroff RR. Generalized staphylococcal scalded skin syndrome in an
    anephric boy undergoing hemodialysis. Arch Dermatol 1984; 120:912–918.


93. Goldberg NS, Ahmed T, Robinson B, et al. Staphylococcal scalded skin syndrome mimicking acute
    graft-versus-host disease in a bone marrow transplant recipient. Arch Dermatol 1989; 125:85–87.


94. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520–532.


95. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with
    vancomycin for the treatment of Staphylococcus aureus bacteremia. Ann Intern Med 1992; 117(5):
    390–398.


96. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant
    Staphylococcus aureus. Curr Opin Infect Dis 2004; 17:549–555.


97. Lewis JS, Ellis MW. Approaches to serious methicillin-resistant Staphylococcus aureus infections
    with decreased susceptibility to vancomycin: clinical significances and options for management.
    Curr Opin Infect Dis 2007; 20:568–573.


98. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998;
    39(3):383–398.

Severe Skin and Soft Tissue Infections in Critical Care 319